GLP-1 Drugs and Kids: 'Is It the Right Thing?'
Key Points:
- Novo Nordisk's Wegovy reduced BMI by an average of 13.5% in children aged 6 to 11, while a diet-and-exercise group saw a 3% BMI increase; however, Wegovy users grew about 1.3 inches less than peers, raising concerns about long-term development.
- Eli Lilly's Zepbound lowered BMI by approximately 18.5% in adolescents without apparent impact on growth, with both drugs improving blood sugar and some cholesterol levels.
- Common side effects included nausea and vomiting, leading up to 17% of trial participants to quit treatment.
- With nearly 20% of US children classified as obese, experts remain divided on whether the benefits of these weight loss injections outweigh the unknown long-term risks.
- The World Health Organization advises against using such medications in children aged 9 and under, and resources like PolitiFact provide guidance for parents considering GLP-1 drugs for their children.